Hester Biosciences' Q3 FY 2025-26 Quarterly Results
- 31 Jan 2026
Result Summary
- Hester Biosciences Ltd reported a 3.2% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Dec (Q3 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 9.9%.
- Its expenses for the quarter were up by 0.1% QoQ and 12.3% YoY.
- The net profit decreased 35.1% QoQ and decreased 18.5% YoY.
- The earnings per share (EPS) of Hester Biosciences Ltd stood at 10.94 during Q3 FY 2025-26.
Financial Statments for Q3 FY 2025-26
Total Income | 78.08 | 80.70 | 71.03 | -3.2% | 9.9% |
Total Expenses | 65.87 | 65.81 | 58.64 | 0.1% | 12.3% |
Profit Before Tax | 12.21 | 14.88 | 12.39 | -17.9% | -1.5% |
Tax | 4.21 | 2.70 | 1.96 | 55.9% | 114.8% |
Profit After Tax | 9.30 | 14.33 | 11.41 | -35.1% | -18.5% |
Earnings Per Share | 10.94 | 16.85 | 13.41 | -35.1% | -18.4% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Hester Biosciences Ltd is a prominent player in the animal healthcare sector, primarily engaged in the development, manufacturing, and marketing of vaccines and healthcare products for poultry and livestock. The company has established itself as a leader in its field, with a focus on producing high-quality vaccines that cater to a range of animal health needs. Hester Biosciences has a significant market presence in India and other countries, contributing to the global animal healthcare industry. Recent developments may include expansions or product launches, but specific details are not available in the provided data.
Revenue
In the third quarter of the fiscal year 2026 (Q3FY26), Hester Biosciences reported a total income of ₹78.08 crores. This represents a decrease of 3.2% compared to the previous quarter (Q2FY26), where the total income was ₹80.70 crores. However, when compared to the same quarter in the previous fiscal year (Q3FY25), the total income showed an increase of 9.9%, from ₹71.03 crores. These figures indicate the company's ability to generate revenue despite fluctuations in quarterly performance.
Profitability
Hester Biosciences' profitability metrics for Q3FY26 show a profit before tax (PBT) of ₹12.21 crores, down 17.9% from ₹14.88 crores in Q2FY26. Compared to Q3FY25, PBT decreased slightly by 1.5% from ₹12.39 crores. The tax expense for Q3FY26 was ₹4.21 crores, reflecting a significant increase of 55.9% from the previous quarter and 114.8% year-over-year. Consequently, the profit after tax (PAT) for Q3FY26 was ₹9.30 crores, a decrease of 35.1% from Q2FY26 and 18.5% from Q3FY25. Earnings per share (EPS) mirrored these trends, decreasing to ₹10.94 from ₹16.85 in Q2FY26 and from ₹13.41 in Q3FY25.
Operating Metrics
The total expenses for Q3FY26 amounted to ₹65.87 crores, representing a marginal increase of 0.1% from ₹65.81 crores in Q2FY26. Year-over-year, total expenses increased by 12.3% from ₹58.64 crores in Q3FY25. These operating metrics provide insight into the company's cost management and operational efficiency. The consistent expenses quarter-over-quarter suggest stability in operational costs, while the year-over-year increase indicates a scaling of operations or increased input costs. These figures are crucial for understanding the operational dynamics and financial health of Hester Biosciences.